VolitionRx Limited announces the launch of its Nu.Q(R) Vet Cancer Screening Test across the U.S. and the forthcoming launch in Europe by Heska Corporation, a leading global provider of advanced veterinary diagnostics, through Heska's veterinary diagnostic laboratories.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.605 USD | -4.12% | -6.92% | -15.62% |
05-14 | Transcript : VolitionRx Limited, Q1 2024 Earnings Call, May 14, 2024 | |
05-13 | VolitionRx Limited Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-15.62% | 50.16M | |
-42.89% | 7.8B | |
+6.77% | 3.53B | |
-27.06% | 1.84B | |
-21.23% | 1.66B | |
+9.31% | 951M | |
+29.42% | 811M | |
-12.66% | 670M | |
-26.12% | 533M | |
+1.19% | 297M |
- Stock Market
- Equities
- VNRX Stock
- News VolitionRx Limited
- Volition Announces the Launch of the Nu.Q(R) Vet Cancer Screening Test in the U.S. and Europe Through Heska's Reference Laboratories